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Pecrease in Circulating Myeloid Dendritic
ell Precursors in Coronary Artery Disease
tilla Yilmaz, MD,* Jana Weber,* Iwona Cicha, PHD,* Christian Stumpf, MD,* Michael Klein, MD,†
ieter Raithel, MD,† Werner G. Daniel, MD,* Christoph D. Garlichs, MD*
rlangen and Nuremberg, Germany
OBJECTIVES We analyzed the frequency of myeloid dendritic cell (mDC) and plasmacytoid dendritic cell
(pDC) precursors in blood of patients with coronary artery disease (CAD) and in
atherosclerotic carotid plaques of patients with cerebrovascular disease (CVD).
BACKGROUND Circulating DC precursors are reduced in several autoimmune diseases. Atherosclerosis has
features of an autoimmune disease, such as the presence of autoantibodies or autoreactive T
cells. Tissue-resident DCs were previously described in atheromata, and it is assumed that
they are important for the activation of T cells against autoantigens there.
METHODS Circulating mDC and pDC precursors were flow cytometrically detected in healthy controls
(n 19), CAD patients with stable (n 20) and unstable angina pectoris (n 19), and acute
myocardial infarction (n  17). In human carotid plaques (n  65), mDC and pDC
precursors were identified immunohistochemically.
RESULTS Circulating mDC precursors were significantly reduced in patients with stable angina pectoris
(0.19%, p  0.04), unstable angina pectoris (0.16%, p  0.004), and acute myocardial
infarction (0.08%, p  0.001) compared with control patients (0.22% of peripheral blood
mononuclear cells). In contrast, pDC numbers were not significantly altered. Circulating
mDC precursors inversely correlated with high-sensitivity C-reactive protein (r  0.38,
p  0.001) or interleukin-6 (r  0.42, p  0.001). In contrast to pDC, significantly more
mDC precursors were observed in vulnerable carotid plaques (24, 0.25 mm2; n  31; p 
0.003) than in stable ones (6.4, 0.25 mm2; n  34).
CONCLUSIONS Similar to autoimmune diseases, circulating mDC precursors were significantly reduced in
patients with CAD. The emergence of mDC precursors in vulnerable plaques suggests their
recruitment into atheromata as a possible reason for their decrease in blood. In contrast, no
significant association of circulating pDC precursors with atherosclerosis was
observed. (J Am Coll Cardiol 2006;48:70–80) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.078Cardiology Foundation
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ruring recent years, several lines of evidence have indicated
hat inflammation and immune reactions are implicated in
therosclerosis and coronary artery disease (CAD). Athero-
clerotic lesions contain large numbers of immune cells,
uch as macrophages, T cells, mast cells, and dendritic cells
DCs). Additionally, a systemic proinflammatory state with
levated serum levels of C-reactive protein (CRP) or inter-
eukin (IL)-6 is detectable in patients with atherosclerotic
ascular diseases (1,2). The importance of immune reactions
or the progression of atherosclerosis was proven in gene-
argeted mouse models with combined defects of immunity
nd apolipoprotein E (3,4). Additionally, a significantly
ncreased cardiovascular risk was observed in patients with
ertain autoimmune disorders, such as rheumatoid arthritis
5) or systemic lupus erythematosus (6).
In previous studies, it was shown that inflammation in
therosclerosis is caused by (auto)immune reactions based
n humoral and cellular immunity against certain (auto)an-
igens. One-fourth of all T cells cloned from human
therosclerotic plaques specifically recognized oxidized low-
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ermany. This work was supported by the Interdisciplinary Center for Clinical Research
f the University of Erlangen-Nuremberg and the German Heart Foundation.d
Manuscript received November 4, 2005; revised manuscript received January 3,
006, accepted January 9, 2006.ensity lipoproteins (oxLDLs) (7,8). Furthermore, autoan-
igens, which play an important role in atherogenesis, are
eat shock proteins (HSPs) (9) and 2-glycoprotein (GP)Ib
10). Serum titers of antibodies against oxLDL (11) or HSP
5 (12) are significantly associated with human carotid
therosclerosis. Chronic infections also were implicated in
he pathogenesis of atherosclerosis. For example, high titers
f antibodies against Chlamydia pneumonia were shown in
atients with CAD (13), and Chlamydia pneumonia often
s detectable in macrophages in atherosclerotic lesions (14).
n that context, it is of great importance that human and
icrobial HSP exhibit a high structural and antigenic
imilarity, which might cause the immune response against
uman HSP by cross immunity, accounting for the associ-
tion between chronic infections and atherosclerosis (15).
he presence of autoantigens in atherosclerosis raised the
uestion whether the vaccination with autoantigens might
lter the progression of atherosclerosis. Indeed, in animal
odels, it was shown that subcutaneous immunization
gainst HSP 65 (16) or 2-GPIb (17) significantly en-
anced atherosclerosis, whereas induction of tolerance by
ral administration of HSP 65 significantly reduced athero-
clerosis (18). In contrast, the immunization against oxLDL
emarkably reduced atherosclerosis (19). The reason for this
iscrepant response might be the induction of high-titer
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July 4, 2006:70–80 Dendritic Cells and Coronary Artery Diseasentibodies against oxLDL by the vaccination, which might
ncrease the clearance of oxLDL from atherosclerotic
esions (20).
Dendritic cells play an important role as professional
ntigen-presenting cells in the immune system because of
heir unique ability to induce a primary immune response by
ctivation of naive T cells (21). Two subtypes of DCs with
ifferent functions exist: 1) myeloid dendritic cells (mDCs),
hich express CD1c, CD11c, and CD33; secrete IL-12
fter stimulation; and usually are activated after contact with
acterial products; 2) plasmacytoid dendritic cells (pDCs)
ith plasma cell-like appearance, which express CD123, the
L-3 receptor -chain, respond to viral infections, and are
he major source of interferon- (22). In recent times, several
pecific antibodies against blood DC antigens (BDCAs) were
eveloped, enabling researchers to investigate the number of
irculating mDC and pDC precursors in different immu-
ological disorders by flow cytometry (23,24). So far,
ignificant alterations of circulating DC precursors were
escribed in autoimmune diseases such as lupus erythema-
osus (25,26), Sjögrens’s syndrome (27), sarcoidosis (28),
llergic asthma bronchiale (29), as well as infectious diseases
uch as human immunodeficiency virus infection (30),
hronic viral hepatitis (31–34), or tuberculosis (35). In lupus
rythematosus, which is a prototype autoimmune disease,
he reduction in circulating DC precursors is inversely
orrelated with disease activity (25,26). It generally is
ssumed that in autoimmune or infectious diseases, the
eduction in circulating DC precursors is caused by their
nhanced recruitment into inflamed tissue.
Analogous to the mucosa-associated lymphoid tissue of
he gastrointestinal tract, a vascular-associated lymphoid
issue consisting of an accumulation of immune cells, which
Abbreviations and Acronyms
AMI  acute myocardial infarction
BDCA  blood dendritic cell antigens
CAD  coronary artery disease
CRP  C-reactive protein
DC  dendritic cell
FITC  fluorescein isothiocyanate
GP  glycoprotein
HLA  human leukocyte antigen
hsCRP  high-sensitivity C-reactive protein
HSP  heat shock protein
IL  interleukin
mDC  myeloid dendritic cell
MI  myocardial infarction
MIP  macrophage inflammatory protein
oxLDL  oxidized low-density lipoprotein
PBMC  peripheral blood mononuclear cell
PCI  percutaneous coronary intervention
pDC  plasmacytoid dendritic cell
PE  phycoerythrin
SAP  stable angina pectoris
UAP  unstable angina pectoriscreen for potentially harmful antigens, was described in the srterial intima (36). It was shown that tissue-resident,
ascular DCs are a key element of this vascular-associated
ymphoid tissue, forming a subendothelial network in the
ntima of healthy children (37). The higher density of
ascular mDC in vascular areas subjected to hemodynamic
tress suggested their role in the initiation of atherosclerotic
esions (37). Compared with initial lesions, advanced ath-
rosclerotic plaques showed a remarkably higher frequency
f vascular mDCs, which exhibited a high level of human
eukocyte antigen (HLA)-DR expression and frequent
-cell contacts, indicating a T-cell activation by vascular
DC during atherogenesis (38,39). Recently, we showed
hat the emergence of tissue-resident, vascular mDCs in
arotid atheromata is associated with a vulnerable plaque
orphology and acute cerebral ischemic events, suggesting
heir role in plaque destabilization (39). Because DCs are
nvolved critically in autoimmune disorders (40), we deter-
ined in the present study the number of circulating DC
recursors in patients with different stages of CAD. Addi-
ionally, mDC and pDC precursor frequency were analyzed
n carotid atheromata to investigate their possible recruit-
ent into atherosclerotic plaques.
ETHODS
atients and controls. Coronary angiography was per-
ormed in all studied patients and healthy controls by a
tandard technique. The patients included in our study had
t least one diseased vessel (75% stenosis). Exclusion
riteria were noncardiac diseases that might interfere with
ur analysis: acute or chronic infections, malignancies,
utoimmune diseases, hyperthyroidism, and medication
ith immunosuppressive agents. Blood samples were taken
ithin 24 h after admission and in the case of myocardial
nfarction also after one week.
The patients were divided into three study groups.
atients with stable angina pectoris (SAP) had a long-term,
table effort angina that had lasted at least three months and
positive exercise test. Unstable angina pectoris (UAP) was
efined as rest pain occurring within 48 h without a recent
yocardial infarction (MI). In those patients, transient
T-T segment depression and T-wave inversion, but no
ignificant elevation of cardiac enzymes, often were present.
riteria of an acute myocardial infarction (AMI) were
ypical angina associated with ST-segment elevations in
lectrocardiogram and at least three occurrences of elevated
erum creatine kinase and troponin-I. The control group
onsisted of subjects who underwent a coronary angiogra-
hy for angina-like symptoms but for whom CAD was
afely excluded by coronary angiogram. The study was
pproved by the institutional ethics committee of the
niversity of Erlangen-Nuremberg, and informed consent
as obtained from all patients and control patients.
erum analysis of proinflammatory markers. The serum
oncentration of high-sensitivity CRP (hsCRP) was mea-
ured using an immunonephelometric assay on a BN II
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Dendritic Cells and Coronary Artery Disease July 4, 2006:70–80nalyzer (Dade Behring, Marburg, Germany) according to
he manufacturer’s instructions. The serum level of IL-6
as analyzed using an enzyme-linked immunosorbent assay
it (R&D Systems, Wiesbaden, Germany) according to the
anufacturer’s instructions.
dentification of DC precursors by fluorescence-activated
ell sorting (FACS). Cell surface antigens were analyzed
mmediately after sample submission. The following fluo-
escein isothiocyanate (FITC)-, phycoerythrin (PE)-, and
E-Cy5-conjugated monoclonal mouse anti-human anti-
odies were used: BDCA1-PE, BDCA2-PE (each from
iltenyi-Biotec, Bergisch Gladbach, Germany), CD14-
E-Cy5, CD18-FITC, CD19-PE-Cy5, CD86-FITC,
LA-DR-FITC (all from Caltag Laboratories, Hamburg,
ermany), CD11a-FITC (BD Pharmingen, Heidelberg,
ermany), and CD40-FITC (Southern Biotechnology,
irmingham, Alabama). Three color-staining and FACS
nalysis were performed according to the strategy, which is
urrently used in the Blood Dendritic Cell Enumeration Kit
f Miltenyi-Biotec (23,24). In contrast to the procedure of
he kit, mDC and pDC precursors were analyzed in separate
amples and, in addition, the FITC channel was used to
nalyze the expression of several markers on mDC and pDC
urface. In brief, in each sample, 200 l of blood was mixed
ith 7 l of anti-CD14-PE-Cy5, 7 l of anti-CD19-PE-
y5, 7 l of anti-BDCA1-PE or anti-BDCA2-PE, 1 to
3 l of a FITC-stained antibody, and 7 l of propidium
odide (BD Pharmingen). Red blood cells were lysed using
igure 1. Gating strategy used for the identification of circulating myeloid
ow cytometry. R1  gating of peripheral blood mononuclear cells accor
catter, B lymphocytes by CD19-staining, monocytes by CD14-staining, and
irculating mDC and pDC precursor as the result of their specific BDCA-1 anFACS lysing solution (Becton Dickinson, Heidelberg,
ermany). Cells were analyzed using a FACSCalibur flow
ytometer with CellQuest software (Becton Dickinson).
ppropriate isotype-matched immunoglobulins (all from
altaq, Burlingame, California) were used as negative
ontrols.
Because circulating DC precursors comprise only 0.1% to
% of peripheral blood mononuclear cells (PBMCs), a
pecial gating strategy was used to analyze mDC and pDC
umbers accurately (Fig. 1). For each sample, 3  105
BMCs were registered in region (R)1 defined by forward
catter and side scatter. In R2, granulocytes were excluded
ccording to their high side scatter, and monocytes, lym-
hocytes, and dead cells were excluded according to their
D14, CD19, and propidium iodide staining, respectively.
irculating mDC and pDC precursors were detected from
he remaining cell population according to their specific
taining for BDCA-1 and BDCA-2 in R3a or R3b,
espectively. The relative cell numbers of mDCs and pDCs
ere determined as a percentage of PBMC based on the
atio of gated cells in R3a and R3b to the gated cells in R1.
he absolute cell numbers of mDCs and pDCs per micro-
iter (cells/l) were calculated based on the relative mDC
nd pDC numbers and the white blood cell count. To
inimize any methodical variations, one blood sample of
ach patient was flow cytometrically analyzed in five inde-
endent experiments, and the median was calculated from
he resulting data to describe mDC and pDC numbers.
ritic cells and plasmacytoid dendritic cell precursors in peripheral blood by
to their forward and side scatter. R2  exclusion of granulocytes by sidedend
dingdead cells by propidium iodide-staining. R3a and R3b  detection of
d BDCA-2 staining, respectively.
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July 4, 2006:70–80 Dendritic Cells and Coronary Artery Diseasedditionally, CD11a, CD18, CD40, CD86, and HLA-DR
xpression on mDC and pDC precursors was analyzed.
istological characterization of atherosclerotic carotid
laques. Atherosclerotic carotid specimens were decalcified
n ethylene diamine tetraacetic acid for 4 days. After paraffin
mbedding, serial cross sections (4 m thick) were cut and
ounted on glass slides. To analyze the plaque morphology,
epresentative sections of each plaque were stained with
richrome. Digital images of atherosclerotic plaques were
btained by a CCD camera (Nikon DXM 1200, Düssel-
orf, Germany). The size of the lipid core and of the total
laque area was analyzed by computer-aided planimetry
Lucia Software V. 4.21, Laboratory Imaging Ltd., Nurem-
erg, Germany). Fibrous cap thickness was measured at its
arrowest site. As described previously (39), atherosclerotic
arotid plaques were subdivided into the following groups:
table (lipid core 50%, fibrous cap 100 M) versus.
ulnerable (lipid core 50%, fibrous cap 100 M).
mmunohistochemical detection of DC precursors in
therosclerotic carotid plaques. For immunohistochemi-
al staining, the following monoclonal antibodies were used:
nti-BDCA-1 for mDC precursors and anti-BCDA-2 for
DC precursors (each from Miltenyi Biotec), anti-fascin for
issue-resident DC (DakoCytomation, Hamburg, Germany),
nd anti-macrophage inflammatory protein (MIP)-3 (R&D
ystems). Immunohistochemial stainings of serial sections
ere performed using the catalyzed signal amplification kit
ccording to the manufacturer’s instructions (CSA System,
akoCytomation, Glostrup, Denmark). In brief, the speci-
ens were treated with 3% hydrogen peroxide to quench
ndogenous peroxidase activity. Then, the specimens were
locked with serum-free protein, followed by incubation
ith the primary antibodies, and then by four sequential
5-min incubations with secondary biotinylated link anti-
ody, streptavidin-biotin-peroxidase complex, biotinyl tyra-
ide (amplification reagent), and streptavidin peroxidase.
inally, brown staining was obtained by incubation with
,3=-diaminobenzidine tetrahydrochloride. Negative con-
rols were treated with irrelevant isotype-matched antibod-
es. Digital cell analyses were performed as previously
escribed (39). Stained cells were identified with a CCD
amera at a magnification of 150 in representative areas of
.25 mm2 of different plaque regions: fibrous cap, plaque
houlders, lipid core, and media. For each plaque, the mean
ell number was calculated from the corresponding cell
umbers of the different plaque regions.
tatistical analysis. Data were expressed as median with
ntire range; p  0.05 was considered statistically signifi-
ant. The nonparametric Mann-Whitney rank sum test was
sed to compare mDC and pDC numbers as well as the
umerical clinical data between the study groups and the
ontrol group (1, SAP vs. CTL; 2, UAP vs. CTL; and 3,
MI vs. CTL). The categorical clinical data were compared
n a similar manner by the Fisher exact test. The correlation
etween mDC or pDC and hsCRP or IL-6 values was
nalyzed by the nonparametric Spearman rank order test. sESULTS
tudy populations. Clinical characteristics of patients with
AD are reported in Table 1 (upper part). In our study,
AD patients with SAP (n 20), with UAP (n 19), and
ith AMI (n  17) were compared with 19 healthy CTLs.
o significant differences were observed with respect to age,
ender, atherogenic risk factors, oral medication, and low-
ensity lipoprotein/high-density lipoprotein cholesterol ra-
io. Patients with UAP and AMI were treated with intra-
enous heparin, aspirin, and nitroglycerin. Percutaneous
nterventions (PCIs) were performed more frequently in
atients with AMI than those with UAP or SAP. Signifi-
antly increased levels of hsCRP and IL-6 were observed in
atients with AMI (hsCRP: 21.8, 1.6 to 73.4 mg/l; IL-6:
0.1, 4.1 to 30.2 pg/ml, p  0.001) compared with CTL
hsCRP: 2.1, 0.7 to 16.7 mg/l; IL-6: 4.4, 0.8 to 9.6 pg/ml),
ndicating a strong proinflammatory systemic state in those
atients. Additionally, patients with AMI had significantly
levated leukocyte counts (12,600, 7,300 to 18,800/l, p 
.001) compared with CTL (6,700, 3,700 to 10,400/l). As
xpected, significantly increased levels of creatine kinase and
roponin-I were observed in patients with AMI. In contrast,
he levels of hsCRP, IL-6, and leukocyte counts did not differ
ignificantly between UAP or SAP compared with CTL. The
alues of other laboratory parameters were not significantly
ltered between all study groups and CTL (data not shown).
To analyze the emergence of DC precursors in athero-
clerotic plaques, carotid specimens from patients with
erebrovascular disease were examined by immunohisto-
hemistry. According to their plaque morphology, patients
ith cerebrovascular disease were subdivided into two
roups: stable versus vulnerable (Table 1, lower part).
laques of 34 patients with stable morphology and of 31
atients with vulnerable morphology were compared. There
ere no significant differences with respect to age, gender,
therogenic risk factors, or oral medication between both
roups. In contrast, ischemic symptoms such as transient
schemic attack, stroke, or amaurosis occurred more often in
atients with classified vulnerable (55%) than those with
table plaques (29%, p  0.04).
ecrease in circulating mDC precursors in CAD. Cir-
ulating mDC and pDC precursors were identified accord-
ng to their expression of BDCA-1 and BDCA-2, respec-
ively, and the absence of the expression of other PBMC
arkers (23,24). In our FACS analyses, mDC numbers
aried between 0.03% and 0.38% (1.6 to 36.6/l) and pDC
umbers between 0.01% and 0.29% (1.0 to 23.0/l). These
alues were in the previously described range (24,34).
Significantly lower percentages of circulating mDC pre-
ursors were observed in patients with SAP (0.19%, 0.03%
o 0.37%, p  0.04), UAP (0.16%, 0.06% to 0.31%, p 
.004), and AMI (0.08%, 0.05% to 0.26%, p  0.001)
ompared with CTL (0.22%, 0.09% to 0.38%) (Fig. 2A). In
ontrast, the percentages of pDC precursors were only
lightly but not significantly reduced in patients with CAD
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Dendritic Cells and Coronary Artery Disease July 4, 2006:70–80Fig. 2B). In a similar way, the absolute numbers of mDC
recursors were significantly lower in patients with SAP
11.3 l, 1.6 l to 36.6 l, p  0.03), UAP (10.3 l, 2.6 l
o 19,8 l, p  0.01), and AMI (9.5 l, 6.7 l to 18,6 l,
 0.01) than in CTL (15.6 l, 7.0 l to 48.5 l) (Fig. 2C).
his fact enabled us to exclude the possibility that a dilution
f mDC precursors by an increase in another PBMC
opulation might have caused their relative reduction in
lood of patients with CAD. The absolute numbers of
irculating pDC precursors were again only slightly, but not
ignificantly reduced in patients with CAD (Fig. 2D).
Furthermore, we monitored the expression of the co-
Table 1. Clinical Data of Patients With CAD
Study Groups CTL
Patients with CAD
No. of patients 19
Age (yrs) 60
Male (%) 37
Atherogenic risk factors (%)
Diabetes 11
Hypertension 74
Smoking 26
Hyperlipidemia 74
Family history of CAD 53
Current medication (%)
Statins 26
Aspirin 42
Beta-blocker 68
ACE inhibitors 21
Multi-3-vessel disease (%) —
LDL/HDL cholesterol ratio 3.2
Percutaneous intervention (%) —
Leukocytes (cells/l) 6,700
hsCRP (mg/l) 2.1
IL-6 (pg/ml) 4.4
Creatinine kinase (U/l) 82
Troponin-I (ng/ml) 0.01
Plaque Morphology
Patients with CVD
No. of patients
Age (yrs)
Male (%)
Atherogenic risk factors (%)
Diabetes
Hypertension
Smoking
Hyperlipidemia
Current medication (%)
Statins
Aspirin
Acute ischemic symptoms (%)
Upper part of the table shows clinical data of healthy controls
pectoris (SAP) and unstable angina pectoris (UAP), and acute m
parameter of the patient groups (SAP, UAP, and AMI) wa
Significant differences between single values of a patient gro
by daggers (†p  0.001). Other values, not marked with
controls. Lower part of the table shows clinical data o
determined stable and vulnerable plaque morphology did
(*p  0.05). Values are reported as median or %.
ACE  angiotensin-converting enzyme; HDL  high-d
IL  interleukin; LDL  low-density lipoprotein.timulatory molecules CD40 and CD86, as well as HLA- gR, and the adhesion molecules CD11a and CD18 on DC
recursors. As previously reported (23,24), only a weak
xpression of CD40 or CD86 on circulating mDC or pDC
recursors was observed (data not shown), which is ex-
lained by their immature state. In contrast, high amounts
f HLA-DR, which is known to be constitutively expressed
n DC precursors (23,24), were found on mDC and pDC
recursors (data not shown). A high expression of CD11a
nd CD18 on both mDC and pDC precursors was ob-
erved. However, the expression of CD40, CD86, HLA-
R, CD11a, or CD18 on circulating mDC or pDC
recursors did not differ significantly between the study
CVD
SAP UAP AMI
20 19 17
66 63 70
55 74 41
30 37 29
85 75 82
10 16 35
95 84 71
25 42 35
50 37 29
65 37 41
70 48 47
55 42 24
20 26 18
2.8 2.4 2.7
75 42 100
6,200 6,500 12,600†
2.2 6.2 21.8†
5.3 6.9 20.1†
68.5 111.5 1,818†
0.02 0.15 31.5†
Stable Vulnerable
34 31
65 72
59 71
41 39
82 81
27 32
68 61
24 36
62 74
29 55*
), coronary artery disease (CAD) patients with stable angina
ial infarction (AMI). Values are reported as median or %. Each
stically compared pairwise with the control group (CTL).
d the corresponding one of the control group are indicated
s, did not differ significantly between patient groups and
brovascular disease (CVD) patients with histologically
differ significantly, except for acute ischemic symptoms
lipoprotein; hsCRP  high-sensitivity C-reactive protein;and
(CTL
yocard
s stati
up an
dagger
f cere
notroups and CTL group (data not shown).
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July 4, 2006:70–80 Dendritic Cells and Coronary Artery DiseaseRegarding the clinical data of the study patients, no
ignificant association of the number of mDC or pDC
recursors with age, gender, atherogenic risk factors, or oral
edication was observed. When comparing SAP or UAP
atients who underwent PCI with those without PCI, no
ignificant changes in mDC or pDC numbers were de-
ected, indicating that PCI itself had no influence on the
ecrease in mDC in our study patients (data not shown).
In patients with AMI, one week after the incident, we
bserved a decrease in hsCRP and IL-6 (Fig. 3A), simul-
igure 2. Relative and absolute frequency of circulating myeloid dendritic
table angina pectoris (SAP, n 20), with unstable angina pectoris (UAP,
ontrols (CTL, n  19). Circulating mDC (A) and pDC (B) precursors
irculating mDC (C) and pDC (D) precursors shown as cells per microli
upper and lower boundary of box), and 10th and 90th percentile (whisk
igure 3. Course of the serum levels of high-sensitivity C-reactive protein
lasmacytoid dendritic cell (pDC; C) precursors in patients with acute myocard
ne week (7 days); ns  not significant.aneously to a partial reconstitution of mDC percentages
Fig. 3B). However, no significant changes of pDC precur-
ors were observed at the follow-up (Fig. 3C).
In our study patients, the number of mDC precursors
ignificantly correlated inversely with hsCRP (Fig. 4A) or
L-6 (Fig. 4B). In contrast, no significant correlation between
DC precursors and hsCRP or IL-6 was detected (Figs. 4C
nd 4D).
ncrease in mDC precursors in vulnerable atherosclerotic
arotid plaques. To assess a possible recruitment of circu-
mDC) and plasmacytoid dendritic cell (pDC) precursors in patients with
9), and acute myocardial infarction (AMI, n 17) compared with healthy
n as a percentage of peripheral blood mononuclear cells (% of PBMC).
lls/l). Graphs show median (line inside box), 25th and 75th percentile
utside box); ns  not significant relative to the control group.
interleukin (IL)-6 (A), circulating myeloid dendritic cell (mDC; B), andcell (
n 1
showand
ial infarction (AMI) during the first 24 h (1 day) and at follow-up after
l
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Dendritic Cells and Coronary Artery Disease July 4, 2006:70–80ating DC precursors into atherosclerotic plaques, immuno-
istochemical stainings of carotid atheromata were per-
ormed. CD1a or CD1c molecules are specifically ex-
ressed on Langerhans cells, a rather immature precursor
orm of mDC in the epidermis, and their expression was
educed upon DC maturation (41,42). Thus, CD1a or
D1c ( BDCA-1) represent excellent surface markers for
DC precursors, and they are nowadays used for their
dentification or isolation from peripheral blood (41). On pDC
recursors, BDCA-2 is specifically expressed, and it is down-
egulated upon DC maturation (23). Therefore, we used the
ame antibodies for the immunohistochemical identification of
DC and pDC precursors in atherosclerotic plaques as in
ACS analysis, BDCA-1 and BDCA-2, respectively. Tissue-
esident DCs were analyzed using an antibody against fascin as
reviously described (39). Furthermore, we analyzed the ex-
ression of MIP-3, the most potent chemokine for the
ttraction of DC precursors into inflamed tissue (43).
Precursors of mDC were detected in all analyzed atheromata
Fig. 5). The localization of mDC precursors corresponded well to
hat of tissue-resident DC. The percentage of mDC precursors to
issue-resident DC varied from 8% to 16%, suggesting a loss of
DCA-1 expression after invasion into the tissue, as described for
DC precursors in the epidermis (42). In contrast, only few pDC
igure 4. Association of circulating dendritic cell (DC) precursors with
bserved between the percentage of circulating myeloid dendritic cell (m
nterleukin (IL)-6 (B). There was a lack of any correlation between pDC a
-axis and logarithmic presentation of hsCRP and IL-6 on x-axis. ns  nrecursors were found in 53 of all 65 atherosclerotic plaques. In tost of the analyzed atherosclerotic plaques, the expression of the
hemokine MIP-3 on macrophage-like cells was observed.
omparing stable plaques of asymptomatic patients with vulner-
ble plaques of patients with acute ischemic symptoms (examples
hown in Fig. 5), higher numbers of mDC precursors, tissue-
esident DC, and MIP-3 but not of pDC precursors seemed to
e present in vulnerable plaques. Indeed, using computer-aided
ell quantification, in vulnerable plaques compared with stable
nes, significantly higher numbers of mDC precursors (24 mm2,
.8 mm2 to 71.3/0.25 mm2 vs. 6.4 mm2, 0.2 mm2 to 53.8/0.25
m2, p  0.003; Fig. 6A), tissue-resident DC (129 mm2, 30.4
m2to 188.8/0.25 mm2 vs. 81.2 mm2, 14.2 mm2 to 188/0.25
m2, p 0.01; Fig. 6C), and MIP-3 (13.6 mm2, 0 to 60.4/0.25
m2 vs. 1.8, 0 to 39.0/0.25 mm2, p  0.002) (Fig. 6D) were
hown. In contrast, pDC numbers did not significantly differ
etween stable and vulnerable plaques (Fig. 6B). Additionally, a
ignificant correlation (r  0.28, p  0.03) between mDC
umbers and MIP-3 -expressing cells was observed (data not
hown), suggesting that MIP-3 attracts mDC precursors into
he atheromata.
ISCUSSION
n previous studies, tissue-resident DCs were detected in
matory and atherogenic markers. A significant inverse correlation was
precursors and serum level of high-sensitivity C-reactive protein (A) or
CRP (C) or IL-6 (D). Linear presentation is shown of mDC or pDC on
nificant.inflam
DC)he intima of susceptible arteries and in advanced athero-
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July 4, 2006:70–80 Dendritic Cells and Coronary Artery Diseaseclerotic plaques (37,38). Particularly in vulnerable plaques,
e previously described a high density of tissue-resident DC
ith frequent T-cell contacts, suggesting their contribution
o plaque destabilization (39). Dendritic cells are able to
egulate the immune response to foreign- as well as self-
ntigens, inducing either an immune response or tolerance
21). Former studies showed that immune reactions are
nvolved in atherogenesis. Therefore, it is assumed that DCs
ight play a key role in those immune reactions in athero-
clerosis.
Three distinct differentiation stages of DCs and their
ypical migratory route are well known (21,44). Dendritic
ells are derived from a common CD34 progenitor in the
one marrow and are released as circulating DC precursors
nto the blood. From the bloodstream, they enter various
issues and develop into tissue-resident, immature DC
here, which are able to take up antigens. In response to
nflammatory signals, their maturation is induced, enabling
ature DCs to activate T cells after their migration into the
igure 5. Immunohistochemical stainings of myeloid dendritic cell (m
BDCA-2), tissue-resident DC (fascin), and the DC-specific chemokine M
magnification, 150). (A) Representative example of an atheroscleroti
symptomatic patient. (B) Representative example of an atherosclerotic pla
ith a transient ischemic attack (TIA). Note the remarkably higher freque
atient with TIA compared with the stable plaque of the asymptomatic pymph nodes. Dependent on the local cytokine environ- dent, tissue-resident, immature DCs might alternatively
rise from monocytes.
In our present study, we investigated whether the previ-
usly reported local increase in tissue-resident DCs in
dvanced atherosclerotic plaques might be associated with
ny changes of the frequency of circulating mDC or pDC
recursors. We showed that the number of mDC precursors
s significantly reduced in blood of patients with stable and
nstable CAD compared with healthy patients. Addition-
lly, patients with AMI exhibited a further temporary
eduction in mDC precursors, which partially normalized
fter one week.
Similar to our observations in CAD, previous studies
howed a decrease in circulating DC precursors in various
utoimmune or infectious diseases. Dependent on the type
f the immunological disease, either a predominant decrease
n mDC precursors (Sjörgren’s syndrome, tuberculosis, and
sthma bronchiale) (27,29,35) or pDC precursors (lupus
rythematosus, chronic hepatitis B and C) (25,26) was
precursors (BDCA-1), plasmacytoid dendritic cell (pDC) precursors
 in the plaque shoulder (PS) and in the lipid core (LC) of carotid plaques
ue with stable morphology (thick fibrous cap, small lipid core) of an
ith a vulnerable morphology (thin fibrous cap, huge lipid core) of a patient
f mDC, tissue-resident DC, and MIP-3 in the vulnerable plaque of the
. Only few pDC precursors were observed in both types of plaques.DC)
IP-3
c plaq
que wescribed. However, it is still yet unclear why different DC
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Dendritic Cells and Coronary Artery Disease July 4, 2006:70–80recursor subtypes are altered in particular immunological
iseases, and this fact might be associated with disease-
pecific immune mechanisms. In those former studies,
ossible mechanisms of the decrease in circulating DC
recursors in inflammatory diseases were investigated, and it
as shown that this decrease was accompanied with a local
C increase in the inflammatory lesions, indicating a
ecruitment of DC precursors from blood into the inflamed
issue (28,31,32,35). Indeed, in a rat model, a rapid DC
recursor recruitment to inflammatory sites was shown after
xposure to an inflammatory stimulus (45).
To elucidate the possibility of DC recruitment into
theromata in our patients with CAD, we analyzed the
mergence of DC precursors in carotid plaques with vul-
erable or stable morphology. Because the acquisition of
omplete coronary plaques is difficult and only possible
ostmortem, we used advanced carotid atheromata instead.
n vulnerable plaques, we found significantly higher num-
ers of mDC precursors than in stable ones, indicating a
ecruitment of mDC precursors particularly at an unstable
tage of atherosclerosis. The expression of MIP-3, which
s the most effective DC chemoattractant (43), was signif-
cantly greater in vulnerable than in stable carotid plaques,
nd it significantly correlated with mDC frequency. Thus, it
s likely that the decrease in circulating mDC precursors in
atients with CAD, particularly those with ACS, is caused
igure 6. Histographic presentation of the frequency of myeloid dendritic c
BDCA-2), tissue-resident DC (fascin), or MIP-3 (cells/0.25 mm2)
ssociation of the number of mDC precursors (A), tissue-resident DC (C)
DC number and plaque morphology was detected (B).y their recruitment into coronary plaques. However, we bannot exclude that other mechanisms, such as apoptosis or
reduced production of mDC precursors in bone marrow,
ight be responsible for their decrease. Because there was a
trong decline of circulating mDC precursors in AMI
atients with a partial recovery after one week, an additional
nvasion into ischemic myocardium might occur in the acute
hase.
In concordance with our results, Weis et al. (46) showed
hat certain atherogenic determinants enhanced adhesion
nd transmigration of mDC across an endothelial cell
onolayer. Additionally, in patients with coronary resteno-
is, a higher mDC number was observed in in-stent reste-
osis probes, suggesting that mDC are recruited into
CI-treated lesions and might be involved in restenosis
47). In our study, we did not observe any differences in
irculating mDC precursors in patients treated with PCI
ompared with those without PCI. However, in contrast to
he study of Skowasch et al. (47), most of our patients had
n ACS.
Beyond local inflammation in atherosclerotic plaques,
everal inflammatory markers, which well correlate with the
therosclerotic burden, were identified in blood of patients
ith atherosclerotic diseases. Among those markers, hsCRP
nd IL-6 were proved to be most powerful in the prediction
f future cardiovascular or cerebrovascular events (1,2). In
he present study, we showed a strong inverse correlation
DC) precursors (BDCA-1), plasmacytoid dendritic cell (pDC) precursors
erosclerotic plaques with stable or vulnerable morphology. Significant
IP-3 (D) with plaque vulnerability. No significant association betweenell (m
in athetween the decrease in circulating mDC precursors and
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July 4, 2006:70–80 Dendritic Cells and Coronary Artery DiseasesCRP or IL-6 levels. Thus, it is likely to assume that the
ecrease in circulating mDC precursors might provide
nother way to predict cardiovascular risk, particularly
ecause mDC precursors were significantly reduced even at
stable stage of atherosclerosis. Therefore, we will investi-
ate their prognostic value, especially in patients with
symptomatic CAD in future prospective studies.
In contrast to the significant decrease in circulating mDC
recursors, circulating pDC precursors were only slightly
educed in patients with CAD. Additionally, we found only
ingle pDC in carotid plaques, and their frequency was not
ssociated with a particular plaque morphology. These
ivergent results about mDC and pDC emergence in
therosclerosis were somehow puzzling, because both DC
ubtypes arise from a common CD34 progenitor form in
he bone marrow. However, the following major differences
etween mDC and pDC, regarding their different migra-
ion pattern and function, might explain the divergent
esults observed in our study. Circulating mDC and pDC
recursors exhibit a very similar pattern of chemokine
eceptors (48). However, in functional studies, it was clearly
emonstrated that the migratory response of mDC and
DC to chemokines profoundly differed (48). Although
DCs mainly are attracted by proinflammatory chemokines
uch as MCP-1 or MIP-3, pDCs respond much more to
he homeostatic CXCL-12, which directs them into lymph
odes (48). In atherosclerosis, immune competent cells are
ainly recruited into inflammatory infiltrates of atheroscle-
otic plaques and not so much into perivascular lymphatic
issue, explaining the higher alterations of circulating mDC
recursors in contrast to circulating pDC precursors.
The results of the present study suggest a recruitment of
irculating mDC precursors into unstable atheromata and
heir crucial involvement in the (auto)immune mechanisms
n atherosclerosis. Recent studies described a connection
etween DC and atherosclerosis-relevant (auto)antigens. In
n vitro studies, it was demonstrated that oxLDL promotes
he maturation of mDCs, enabling them to induce T-cell
ctivation (49, 50). In addition, we recently showed the
lustering of mDC particularly in lipid-rich areas of ad-
anced atherosclerotic plaques (39). Furthermore, Bobry-
hev and Lord (51) observed frequent cell contacts of T cells
nd vascular mDC, which highly expressed HSP 70, indi-
ating an mDC-induced T-cell activation against HSP 70.
ith regard to chronic infections, the presence of Chla-
ydia pneumoniae was described in the cytoplasm of
ascular mDC, suggesting that chlamydial proteins might
e intracellularly processed and subsequently expressed on
he surface of vascular mDC (52). Moreover, the expression
f the collagen-like complement component C1q, which is
mportant for the presentation of immune complex-
ssociated antigens, was described on vascular mDCs (53).
verall, at present, there is increasing evidence suggesting
n important role of vascular mDC in the immune response
o certain (auto)antigens accelerating atherogenesis. How-
ver, future studies will have to determine whether aepletion or specific suppression of DC might change the
ourse of atherosclerosis.
onclusions. Our study showed a significant decrease in
irculating mDC precursors in patients with CAD, partic-
larly those with ACS, similar to the reductions observed in
utoimmune or infectious diseases. The accumulation in
DC precursors in vulnerable atherosclerotic plaques sug-
ests that the decrease in circulating mDC precursors is
aused by their recruitment into the vessel wall. Because
Cs are strong T-cell stimulators, inflammation might be
nhanced by their invasion into atheromata, leading to
laque progression and destabilization.
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